» Articles » PMID: 7294765

Liquid Chromatographic Assay for Metronidazole and Tinidazole: Pharmacokinetic and Metabolic Studies in Human Subjects

Overview
Specialty Pharmacology
Date 1981 May 1
PMID 7294765
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

We developed methods for measuring metronidazole, its two major metabolites, and tinidazole in serum and urine. After treatment of each sample with an equal volume of 5% perchloric acid, the drugs were separated by reverse-phase high-pressure liquid chromatography (retention times, 6 to 18 min). Quantitation was based on spectrometry at 320 nm. These assays were sensitive, rapid, and specific, and recoveries from biological samples were quantitative. Metronidazole and tinidazole were given as rapid intravenous infusions to four healthy human volunteers. The biological half-lives of these two compounds were 5.4 and 11.1 h, respectively. The hydroxy metabolite of metronidazole appeared quickly in serum and was eliminated at a slow rate. The acetic acid metabolite of metronidazole was detected in serum at very low levels and only for a limited time. No metabolic products of tinidazole were found in serum samples. In urine, 43.7% of the administered dose of metronidazole was recovered over a period of 24 h (24.1% of the dose as the hydroxy metabolite, 12.0% as the acetic acid metabolite, and 7.6% as unchanged drug). Only 18.4% of the infused dose of tinidazole was eliminated in urine over a period of 72 h, and no metabolic products were detected.

Citing Articles

Electrochemical Behaviour of Tinidazole at 1,4-Benzoquinone Modified Carbon Paste Electrode and Its Direct Determination in Pharmaceutical Tablets and Urine by Differential Pulse Voltammetry.

Nikodimos Y, Hagos B J Anal Methods Chem. 2017; 2017:8518707.

PMID: 29250454 PMC: 5698602. DOI: 10.1155/2017/8518707.


The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst.

Pearce R, Cohen-Wolkowiez M, Sampson M, Kearns G Drug Metab Dispos. 2013; 41(9):1686-94.

PMID: 23813797 PMC: 3876806. DOI: 10.1124/dmd.113.052548.


Systemic antibiotic therapy for chronic osteomyelitis in adults.

Spellberg B, Lipsky B Clin Infect Dis. 2011; 54(3):393-407.

PMID: 22157324 PMC: 3491855. DOI: 10.1093/cid/cir842.


Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.

Lamp K, Freeman C, Klutman N, Lacy M Clin Pharmacokinet. 1999; 36(5):353-73.

PMID: 10384859 DOI: 10.2165/00003088-199936050-00004.


Metronidazole. A therapeutic review and update.

Freeman C, Klutman N, Lamp K Drugs. 1997; 54(5):679-708.

PMID: 9360057 DOI: 10.2165/00003495-199754050-00003.


References
1.
Stambaugh J, FEO L, Manthei R . The isolation and identification of the urinary oxidative metabolites of metronidazole in man. J Pharmacol Exp Ther. 1968; 161(2):373-81. View

2.
Houghton G, Thorne P, Smith J, Templeton R, Collier J . Comparison of the pharmacokinetics of metronidazole in healthy female volunteers following either a single oral or intravenous dose. Br J Clin Pharmacol. 1979; 8(4):337-41. PMC: 1429835. DOI: 10.1111/j.1365-2125.1979.tb04715.x. View

3.
Welling P, Monro A . The pharmacokinetics of metronidazole and tinidazole in man. Arzneimittelforschung. 1972; 22(12):2128-32. View

4.
Midha K, McGilveray I, Cooper J . Determination of therapeutic levels of metronidazole in plasma by gas-liquid chromatography. J Chromatogr. 1973; 87(2):491-7. DOI: 10.1016/s0021-9673(01)91751-0. View

5.
Ralph E, Clarke J, Libke R, Luthy R, KIRBY W . Pharmacokinetics of metronidazole as determined by bioassay. Antimicrob Agents Chemother. 1974; 6(6):691-6. PMC: 444721. DOI: 10.1128/AAC.6.6.691. View